First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

BACKGROUND: Bisphosphonates reduce the risk of skeletal events in patients with malignant bone disease, and zoledronic acid has shown potential anticancer effects in preclinical and clinical studies. We aimed to establish whether bisphosphonates can affect clinical outcomes in patients with multiple...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Morgan, Gareth J, Davies, Faith E, Gregory, Walter M, Cocks, Kim, Bell, Sue E, Szubert, Alex J, Navarro-Coy, Nuria, Drayson, Mark T, Owen, Roger G, Feyler, Sylvia, Ashcroft, A John, Ross, Fiona, Byrne, Jennifer, Roddie, Huw, Rudin, Claudius, Cook, Gordon, Jackson, Graham H, Child, J Anthony
Formato: Artigo
Idioma:Inglês
Publicado em: Lancet Publishing Group 2010
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3639680/
https://ncbi.nlm.nih.gov/pubmed/21131037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(10)62051-X
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados